Menu
Search
|

Menu

Close
X

Mediwound Ltd MDWD.OQ (NASDAQ Stock Exchange Global Market)

4.35 USD
+0.00 (+0.00%)
As of Feb 23
chart
Previous Close 4.35
Open 4.35
Volume 400
3m Avg Volume 5,715
Today’s High 4.35
Today’s Low 4.35
52 Week High 8.25
52 Week Low 3.60
Shares Outstanding (mil) 26.35
Market Capitalization (mil) 135.72
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
2
FY16
2
FY15
1
EPS (USD)
FY17
-0.556
FY16
-0.864
FY15
-0.998
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
62.40
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-52.80
14.43
Return on Equity (TTM)
vs sector
-240.59
16.13

EXECUTIVE LEADERSHIP

Stephen Wills
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Cal Cohen
Chief Executive Officer, Since 2006
Salary: --
Bonus: --
Sharon Malka
Chief Financial Officer, Since 2007
Salary: --
Bonus: --
Eilon Asculai
Vice President, Research & Development, Since 2007
Salary: --
Bonus: --
Lior Rosenberg
Chief Medical Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

42 Hayarkon Street
YAVNE     8122745

Phone: +9728.9324010

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

SPONSORED STORIES